Epiglottitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 158: Line 158:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen'''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 2 g IV q4-6h'''''<BR> OR <BR> ▸ '''''[[Oxacillin]] 2 mg IV q4-6h'''''<BR> OR <BR> ▸ '''''[[Cefazolin]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Vancomycin]] 15 mg/kg IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Dicloxacillin]] 500 mg PO q6h'''''<BR> OR <BR> ▸ '''''[[Cephalexin]] 500 mg PO q6h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 300 mg PO q6h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 300 mg PO q8h'''''<BR> OR <BR> ▸ '''''[[TMP/SMX]] 160/800 mg PO q12h'''''
|-
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Meticilling resistant Staphylococcus aureus''}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Meticilling resistant Staphylococcus aureus''}}
Line 221: Line 217:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen'''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amoxicillin-Clavulanic acid]] 850/125 mg PO q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amoxicillin-clavulanic acid]] 850/125 mg PO q24h'''''
|-
|-
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azitromycin]] 500 mg PO q24h one day, then 250 mg PO q24h'''''<BR> OR <BR>▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azithromycin]] 500 mg PO q24h one day, then 250 mg PO q24h'''''<BR> OR <BR>▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL>
|-
|-
|}
|}
Line 252: Line 248:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azytromycin]] 2 g PO single dose'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azythromycin]] 2 g PO single dose'''''
|-
|-
|}
|}
Line 267: Line 263:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Alternative Regimen'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceforoxime]] 500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]] 750 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Doxycyclin]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin-clavulanic acid]] 850/125 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefuroxime]] 500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]] 750 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin-clavulanic acid]] 850/125 mg PO q12h'''''
|-
|-
|}
|}

Revision as of 13:47, 20 May 2014

Epiglottitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Epiglottitis from other Diseases

Epidemiology and Demographics

Screening

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Rays

ECG

CT scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Epiglottitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Epiglottitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Epiglottitis medical therapy

CDC on Epiglottitis medical therapy

Epiglottitis medical therapy in the news

Blogs on Epiglottitis medical therapy

Directions to Hospitals Treating Epiglottitis

Risk calculators and risk factors for Epiglottitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Medical Therapy

Patients should receive empiric antibiotic treatment after sample for throat culture has been taken. The recomended treatment is a combination of a third generation cephaplosporin such as ceftriaxone or cefotaxime with an antistaphylococcal agent, active against.Template:Cita publicación

Empiric Therapy Adapted from Lancet. 2012;380(9854):1693-702.[1] and Clin Infect Dis. 2004;39(9):1267-84.[2]

Pediatric patient
Preferred Regimen
Vancomycin 10 mg/kg per dose IV q4h
PLUS
Ceftriaxone 50-75 mg/kg administered IV q24h
OR
Cefotaxime 50 mg/kg IV q8h
Alternative Regimen (If Allergic to Penicillin)
Clindamycin 7.5 mg/kg mg IV q6h
PLUS
Levofloxacin 100 mg/kg IV q24h
Adult patient
Preferred Regimen
Vancomycin 1 g IV q12h
PLUS
Ceftriaxone 2 g IV q24h
OR
Cefotaxime 2 g IV q8h
Alternative Regimen (If Allergic to Penicillin)
Clindamycin 600-900 mg IV q6h
PLUS
Levofloxacin 750 mg IV q24h

Pathogen based theerapy

▸ Click on the following categories to expand treatment regimens.


Bacteria

  ▸  Streptococcus pneumoniae

  ▸  Streptococcus sp

  ▸  Staphylococcus aureus

  ▸  Haemophilus influenzae type B

  ▸  Klebsiella pneumoniae

  ▸  Moraxella catarrhalis

  ▸  Neisseria sp

  ▸  Pasteurella multocida

  ▸  Pseudomonas sp

Haemophilus influenzae
Preferred Regimen
Meropenem 2 g IV q8h
Alternative Regimen
Colistin 1.25 mg/kg IV q6—12h
OR
Polymyxin B 0.75—1.25 mg/kg IV q12h
Streptococcus pneumoniae
Preferred Regimen (sussceptible to penicillin)
Penicillin G 2 million units IV q4h
OR
Ceftriaxone 2 g IV q24h
OR
Clindamycin 600 mg IV q6h
Alternative Regimen (penicillin resistant strains)
Moxifloxacin 400 mg IV q24h
OR
Levofloxacin 750 mg IV q24h
OR
Vancomycin 1 g IV q12h
OR
Linezolid 600 mg IV q12h
OR
Ceftaroline 600 mg IV q12h
Streptococcus pyogenes Streptococcus viridans
Meticillin susceptible Staphylococcus aureus
Preferred Regimen
Nafcillin 2 g IV q4-6h
OR
Oxacillin 2 mg IV q4-6h
OR
Cefazolin 2 g IV q8h
OR
Vancomycin 15 mg/kg IV q8h
Alternative Regimen
Dicloxacillin 500 mg PO q6h
OR
Cephalexin 500 mg PO q6h
OR
Clindamycin 300 mg PO q6h
OR
Clindamycin 300 mg PO q8h
OR
TMP/SMX 160/800 mg PO q12h
Meticilling resistant Staphylococcus aureus
Preferred Regimen
Vancomycin 15-20 mg/kg IV q8-12h
OR
Daptomycin 4-6 mg/kg IV q24h
OR
Linezolid 600 mg IV q12h
Alternative Regimen (Vancomycin intermmediate sussceptibility)
Linezolid 600 mg/kg IV q12h
OR
Daptomycin 4-6 mg/kg IV q24h
OR
Ceftraoline 600 mg IV q8h
Alternative Regimen (Vancomycin resistance)
Teicoplanin 6 mg/kg IV q12h (total of three doses), 6 mg/kg IV q24h
OR
Telavancin 10 mg/kg q24h (1 hour infusion)
OR
Linezolid 600 mg/kg IV q12h
OR
Daptomycin 4-6 mg/kg IV q24h
Haemophilus influenzae
Preferred Regimen
Ceftriaxone 2 g IV q12h
OR
Cefotaxime 2 g IV q8h
Alternative Regimen
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg IV q8h
Klebsiella pneumoniae
Preferred Regimen
Ceftriaxone 2 g IV q12h
OR
Cefotaxime 2 g IV q8h'
OR
Levofloxacin 750 mg IV q24h
Alternative Regimen
Imipenem 500 mg IV q6h
OR
Meropenem 1 g IV q8h'
OR
Ertapenem 1 g IV q24h
Moraxella catrrhalis
Preferred Regimen
Amoxicillin-clavulanic acid 850/125 mg PO q24h
Alternative Regimen
Azithromycin 500 mg PO q24h one day, then 250 mg PO q24h
OR
TMP/SMZ 5 mg/kg IV q6—12h (TMP component)
Neisseria meningitidis
Preferred Regimen
Ceftriaxone 2 g IV q12h
OR
Cefotaxime 2 g IV q6h'
Alternative Regimen
Penicillin G 4 million units IV q4h
OR
Chloramphenicol 100 mg/kg/day q6h, not exceed 4 g
Neisseria gonorrhoeae
Preferred Regimen
Ceftriaxone 250 mg IM single dose
Alternative Regimen
Azythromycin 2 g PO single dose
Pasteurella maltocida
Preferred Regimen
Penicillin VK 500 mg PO q12h
OR
Amoxicillin 500 mg PO q8h
OR
Amoxicillin-clavulanic acid 850/125 mg PO q12h
Alternative Regimen
Cefuroxime 500 mg PO q12h
OR
Levofloxacin 750 mg PO q24h
OR
Moxifloxacin 400 mg PO q24h
OR
Doxycycline 100 mg PO q12h
OR
Amoxicillin-clavulanic acid 850/125 mg PO q12h
Pseudomona sp
Preferred Regimen
Ceftazidime 2 g IV q8h
OR
Cefepime 2 g IV q8h
PLUS
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg PO q24h
Alternative Regimen (combination of)
TMP/SMZ 5 mg/kg IV q6—12h (TMP component)

Other treatments may include:

References

  1. van de Beek, D.; Brouwer, MC.; Thwaites, GE.; Tunkel, AR. (2012). "Advances in treatment of bacterial meningitis". Lancet. 380 (9854): 1693–702. doi:10.1016/S0140-6736(12)61186-6. PMID 23141618. Unknown parameter |month= ignored (help)
  2. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al. (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (9):1267-84. DOI:10.1086/425368 PMID: [1]